We are creating a future that defeats cancer. Empowering patients to fight their cancer through next-gen CAR-T technologies.
Adelaide, South Australia
Joined May 2017
- Tweets334
- Following478
- Followers407
- Likes1.3K
Honoured to be named in @theTiser's Top 100 Female Founders & Executives 2026! 🙏
At @CarinaBiotech we're developing next-gen CAR-T therapies to defeat cancer — this recognition fuels our mission further. The fight continues. 🧬
Carina Biotech is redefining CAR-T therapy for solid tumours with its first-in-class LGR5+ program, CNA3103.
🎟 Register for the #AUCARTShowcase: lnkd.in/gvfP5VYH
Discover how Carina’s rapid 24-hour CAR-T generation process and deep pipeline are driving the next frontier in solid tumour treatment.
📧 Inquiry: [email protected]
Carina Biotech’s CNA3103 #CAR_T cells show how next-gen immunotherapy can target & destroy solid tumours like colorectal cancer. 💡Learn more: carinabiotech.com/our-techno…
Honoured to be among The @Australian’s Top 100 Innovators 2025.
📧 Investor Inquiries: [email protected]
Freshly named in @TheAustralian’s Top 100 Innovators 2025, Carina Biotech is advancing first-in-class #CAR_T therapies for solid cancers.
Explore the milestones and pipeline behind CNA3103, our lead therapy targeting colorectal cancer.
📩 Investor Inquiry: [email protected]
🚀 Honoured to be featured in The @Australian’s Top 100 Innovators 2025.
Carina Biotech continues to drive Australia’s leadership in #CAR_T innovation. Colorectal cancer remains a major health challenge with ~15.5K new cases a year; 5-year survival ~71%. #Biotech #CancerResearch
📩 Investor Inquiries: [email protected]
➡️ Learn more: carinabiotech.com
🔗 Meet the 100 innovators transforming Australia: bit.ly/4nGR5lz
#TheAustralian #AustralianInnovation #Biotech #CAR_T #CancerResearch #Oncology #LifeSciences
Our CEO, Dr Deborah Rathjen, will moderate the investor panel at #BiotechShowcase 2025 hosted by @PeakAsset1 & @MonsoonComms—joined by experts from Bioshares, @UniseedFund & Tenmile.
🔗Register now: bit.ly/ZOOM-BiotechShowcase2…
Our CEO, Dr Deborah Rathjen, joins the AU CAR-T Showcase on Tue, 12 Aug in Melbourne, hosted by @MonsoonComms & @FB_Rice.
🔗 Register: bit.ly/reg-cart
#CART #Biotech #ASX #CancerResearch
Carina Biotech has raised $5M, bringing total Series A to $32M, to progress its CAR-T clinical trial in advanced colorectal cancer.
🇦🇺 First AU CAR-T to pass US FDA IND & run trials locally.
We sincerely thank the investors for backing our mission.
#ImmunoOncology #Biotech
For inquiries & participation in future fund raising, contact us at [email protected]
#CarinaBiotech
Hear how Carina Biotech’s lean team of 5 is advancing personalised CAR-T therapies targeting colorectal, ovarian & gastric cancers.
🌟 Phase 2 expected H2 2025.
Tune in now @Marcus_Today ⬇️
bit.ly/3Znnfrs
Carina Biotech retweeted
Join us at our #BiotechShowcase on Wed 21 Aug for a series of top Aussie #biotech presentations, panel on biotech investing and networking drinks. Don’t miss out: peak.contact/
CEO & MD Dr Deborah Rathjen, Dr Carmela Ricciardelli, Dr Veronika Bandara & Annabell Leske presented posters on Carina’s LGR5-targeting CAR-T program at #AACR24. The posters were well attended & drew interest from pharma & investors. View the posters: bit.ly/3UnNQ6k
Carina is pleased be presenting 3 posters from studies of its LGR5-targeting CAR-T program in colorectal and ovarian cancer at the @AACR Annual Meeting in San Diego, 5-10 Apr. More detail on the poster presentations can be found in our press release: bit.ly/3PsG7RS
Join us in Melbourne tomorrow as CEO & Managing Director Dr Deborah Rathjen presents Carina’s first-in-class CAR-T treatment CNA3103 for colon cancer at @MonsoonComms' Twilight investor briefing!
We’re kickstarting our Twilight series this Wednesdau with global lysyl oxidase enzymes leader @SyntaraTx & CAR-T immunotherapy company @CarinaBiotech. Join us for presentations followed by drinks & canapes, kindly sponsored by @FB_Rice!
Register: forms.gle/hh1GC9Ti8vbWvvm37
CEO Deborah Rathjen will present Carina’s investigational colon cancer treatment CNA3103 at Biotech Showcase the premier platform for private & micro mid-cap companies.
Carina is pleased to announce it has dosed the first patient in its Phase 1/2a LGR5-targeting CAR-T therapy (CNA3103) for advanced colorectal cancer, a significant milestone as Carina advances its potentially revolutionary targeted cancer treatment option: bit.ly/41wiIE0
First patient enrolled! A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | ClinicalTrials.gov : bit.ly/47rI5Zb
